title: Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus.
abstract: BACKGROUND
  Patients with systemic lupus erythematosus (SLE) have persistent platelet activation and an increased risk of thrombotic events, which cannot be accounted for by traditional cardiovascular risk factors. Factor (F)XII has a potentially important role in thrombus formation and is triggered by activated platelets. We therefore asked whether the contact system is involved in inflammation and vascular disease (VD) in SLE.
  
  
  METHODS
  Fibrin clots were incubated with purified FXII or whole blood, and the activation and regulation of FXII were studied. Plasma from SLE patients with (n = 31) or without (n = 38) previous VD and from matched healthy controls (n = 68) were analyzed for the presence of complexes formed between contact system enzymes and antithrombin (AT) or C1 inhibitor (C1INH) and evaluated with regard to clinical data and laboratory parameters.
  
  
  RESULTS
  Fibrin clots elicited FXII activation and acted as co-factors for AT. In clotting plasma, the levels of FXIIa-AT increased, and FXIIa-C1INH decreased. A similar reciprocal relationship existed in SLE patients. FXIIa-AT was elevated in the SLE patients with a history of VD, while the corresponding levels of factor FXIIa-C1INH were significantly decreased. FXIIa-AT correlated strongly with platelet parameters. The odds ratio for VD among the SLE patients was 8.9 if they had low levels of FXIIa-C1INH, 6.1 for those with high levels of FXIIa-AT, and increased to 23.4 for those with both decreased levels of FXIIa-C1INH and increased levels of FXIIa-AT.
  
  
  CONCLUSIONS
  Activation of FXII is elicited by fibrin during thrombotic reactions in vitro and in vivo, and fibrin acts as a heparin-like co-factor and regulates AT. Patients with SLE had altered levels of FXIIa-serpin complexes, supporting that the contact system is involved in this disease. FXIIa-serpin complexes are strongly associated with previous VD in SLE patients, suggesting that these complexes are potential biomarkers for monitoring and assessing the risk of thrombotic events in SLE.
authors.forename: Jennie
authors.initials: J
authors.lastname: Bäck
authors.forename: Christian
authors.initials: C
authors.lastname: Lood
authors.forename: Anders A
authors.initials: AA
authors.lastname: Bengtsson
authors.forename: Kristina Nilsson
authors.initials: KN
authors.lastname: Ekdahl
authors.forename: Bo
authors.initials: B
authors.lastname: Nilsson
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000502:physiology*; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005174:Factor XII / Q000378:metabolism; D005260:Female; D005337:Fibrin / Q000378:metabolism; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015843:Serpins / Q000378:metabolism; D013927:Thrombosis / Q000097:blood / Q000209:etiology*
chemical_list: D015415:Biomarkers; D015843:Serpins; D005174:Factor XII; D005337:Fibrin